ClinicalTrials.gg
RecruitingNCT05722405Updated Jan 5, 2026

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

A Phase 4 interventional study of Ixazomib plus low-dose lenalidomide and Ixazomib in Multiple Myeloma, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Registered 7 months after the study started (first participant enrolled Jul 2022, registered Feb 2023).
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies testing ixazomib in Multiple Myeloma — 1 open to participants now, 7 under way, none of them phase 3. ixazomib · Multiple Myeloma.

Planned enrollment
16th of 68
100 · median 48
Started
2022
with 1 other
Phase 4
4 of 68
1 open now
Registered
68th of 68
by date

Among the 68 studies testing ixazomib in Multiple Myeloma, this one is the 16th largest by planned enrollment, is one of 2 that started in 2022, is one of 4 in phase 4, and was the 68th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

1 of the 68 studies testing ixazomib in Multiple Myeloma is open now, in 1 country.

By country, each count listing its studies:

About ixazomib

ixazomib: first FDA approval 2015 (NINLARO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies testing ixazomib in Multiple Myeloma, or all of them as a file.
02

Study summary

Ixazomib combined with low-dose lenalidomide(10mg) vs Ixazomib alone as maintenance regimen in patients with high-risk multiple myeloma after induction and consolidation of VRD-based regimen.

Read the detailed description

This study was designed to investigate whether the oral proteasome inhibitor ixazomib combined with low-dose lenalidomide(10mg) as a maintenance regimen could improve the outcome and prognosis of patients with high-risk multiple myeloma after induction and consolidation of VRD-based regimen.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • high risk multiple myeloma
  • Ixazomib
  • low-dose lenalidomide
  • maintenance therapy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with a confirmed diagnosis of symptomatic multiple myeloma with high-risk genetic features (1q21 amplification/t(4;14)/t(14;16)/t(14;20)/17p deletion/TP53 mutation) according to IMWG 2016 criteria.
  2. 0-3
  3. After induction and consolidation of the VRD regimen (where patients younger than 65 years of age who are eligible for HSCT and are willing to undergo autologous HSCT collect stem cells and complete autologous HSCT after 3 courses and continue bortezomib or Ixazomib continuous therapy while awaiting transplantation and complete post-transplant consolidation; patients who are not eligible for HSCT regulation or refuse to undergo autologous HSCT go directly to consolidation after induction therapy) and are willing to receive maintenance therapy.
  4. Expected survival beyond 6 months
  5. Age 18 to 80 years.
  6. Adequate renal, hepatic, pulmonary and cardiac function, defined as follows (as estimated by Cockcroft-Gault) ≥ 60 ml/min (except for abnormal renal function due to multiple myeloma).

    Serum and AST below 2.5 times the Total below 1.5 times the upper limit of normal Cardiac ≥ 50%, no pericardial effusion confirmed by echocardiography, no electrocardiographic findings Absence of clinically significant pleural effusion Baseline oxygen saturation ≥ 95% while indoors

  7. Serum or urine pregnancy tests must be negative in women of (women who have undergone sterilization or are at least 2 years may be considered infertile), and patients treated with lenalidomide should have strict and birth control measures.
  8. Patients are able to comply with the trial protocol as judged by the investigator.
  9. Patients voluntarily participate in this clinical trial, understand the study procedures and are able to sign the in writing.

Exclusion criteria

Exclusion Criteria:

  1. Presence of fungal, bacterial, viral or other infections that are uncontrollable or require IV antimicrobial therapy. Presence of simple urinary tract infection and uncomplicated bacterial pharyngitis, after consultation with the investigator, if responsive to active treatment.
  2. Known presence of or a history of (HBsAg positive) or viral (anti-HCV positive) infection. A history of treated hepatitis B or hepatitis C is allowed if a viral load undetectable by quantitative PCR and/or nucleic acid testing is present.
  3. A history of thrombosis within six months.
  4. presence of a history of other than carcinoma in situ (e.g., cervical, bladder, breast, thyroid), except in patients who have not had an episode for at least 3 years
  5. Patients with uncontrolled arrhythmias and a history of myocardial infarction, cardiac angioplasty or stenting, unstable angina or other cardiac disease within 12 months of enrollment.
  6. The presence of a significant immunodeficiency.
  7. The presence of any medical condition that may interfere with the assessment of the safety or efficacy of the treatment.
  8. A history of severe reactions to this investigational drug.
  9. Any pregnant or breastfeeding female of .
  10. Male and female subjects who are unwilling to use within 6 months from the time of signing the consent form until the completion of the administration of this study.
  11. Subjects who, in the judgment of the investigator, are unlikely to complete all study visits or procedures required by the protocol, including follow-up visits or compliance with the requirements for participation in the study.
  12. History of disease (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) within the past 2 years that causes end-organ damage or requires systemic /systemic disease-modifying drugs.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Ixazomib

    Ixazomib as the single drug for maintenance. This group as control arm

    Drug: Ixazomib

  • Experimental
    Ixazomib plus low-dose lenalidomide

    Ixazomib combined with low-dose lenalidomide(10mg) for maintenance

    Drug: Ixazomib plus low-dose lenalidomide

Interventions

  • DrugIxazomib plus low-dose lenalidomide

    Drug pages: IxazomibStudies of IxazomibIxazomib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LenalidomideStudies of LenalidomideLenalidomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Whether Ixazomib combined with low-dose lenalidomide improves the outcome and prognosis of patients with high-risk multiple myeloma as a maintenance treatment option compared to ixazolomib alone

    Also known as: Ninlaro

  • Ixazomib alone

    Also known as: Ninlaro

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from the date of first dose of study drug to the first occurrence of PD as evaluated by the investigator or death from any cause, whichever occurs first. PD is defined as \>=25% increase from lowest value in serum M component or urine M-component; difference between involved and uninvolved free light chain (FLC) levels (absolute increase \>10 mg/dL); bone marrow plasma cell percent \>/=10%; new bone lesions or soft tissue plasmacytomas development or definite increase in existing bone lesions/soft tissue plasmacytomas size; hypercalcaemia development.

    Time frame: through study completion, a average of 1 year

Secondary outcomes

  1. Very Good Partial Response (VGPR) + Complete Response (CR) Rate

    Using IMWG criteria

    Time frame: through study completion, a average of 1 year

  2. Overall Survival (OS)

    OS is measured as the time from the date of first dose of study drug to the date of death.

    Time frame: through study completion, a average of 1 year

  3. Percentage of Participants with Adverse Events (AEs)

    Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after the last dose of study drug.

    Time frame: through study completion, a average of 1 year

07

Study locations

1 of 1 sites recruiting
  • Yang Xu
    Hangzhou, Zhejiang 310009, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jun 2026, 47 months after the start.

Of 28 phase 4 interventional studies under Multiple Myeloma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 57. This study's planned 47 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2023
First posted
Feb 10, 2023
StartActual
Jul 1, 2022
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jul 31, 2028
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05722405
Collaborators
Affiliated Hospital of Jiaxing University, Huzhou Central Hospital, Lishui Country People's Hospital, Dongyang People's Hospital, Shangyu People's Hospital, Shaoxing People's Hospital, Shaoxing Second Hospital
Responsible party
Sponsor
First posted
Feb 10, 2023
Start date
Jul 1, 2022
Primary completion
Jun 30, 2026 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Jan 5, 2026

Study contacts

Xuzhao Zhang, Dr.
Contact
zxzzju@zju.edu.cn
(086)571-89713679
Yang Xu, Dr.
study director · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ixazomib · Lenalidomide

Start the discussion